Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: A slimmer AstraZeneca starts to look tasty

This article was originally published in Scrip

Executive Summary

The headline number when AstraZeneca announced its full-year 2011 results on February 2 was not the sales or earnings numbers, but the 7,300 further job losses from R&D, sales and marketing, and manufacturing (, 3 February 2012). The AstraZeneca share price finished the day down nearly four percent as investors' concerns with the lacklustre financial results and 2012 outlook were compounded by another restructuring.

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts